Star Lake Bioscience Co., Inc.Zhaoqing Guangdong(600866.SS)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 1,116 | 4,071 | 17,486 | 17,374 | 17,334 | 15,900 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 149 | 152 | 608 | 678 | 943 | 979 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1964 and headquartered in Zhaoqing, China, Star Lake Bioscience Co., Inc. specializes in the production and global distribution of pharmaceutical ingredients, as well as food and animal feed additives. Its extensive product catalog includes guanosine, which serves as a crucial intermediate for both food and pharmaceutical applications. The company also manufactures L-proline, a vital intermediate for synthesizing captopril and enalapril, and a raw material used in amino acid transfusions. Another key offering is Adefovir dipivoxil tablets, formulated to combat Hepatitis B by inhibiting HBV DNA polymerase activity and disrupting the virus's DNA. Additionally, L-threonine is provided for its application in animal feed premixes, particularly for pigs and poultry. Star Lake Bioscience further supplies disodium 5'-ribonucleotide, utilized in the treatment of chronic hepatitis, muscular atrophy, and certain eye conditions. Similarly, disodium 5-inosinate addresses issues like leukopenia, thrombocytopenia, and both acute and chronic hepatitis. Inosine is another significant product, prescribed for various ailments including chronic hepatitis, heart disease, low white blood cell or platelet counts, and central choroidoretinitis. Furthermore, disodium 5'-guanylate finds application in food preservation, such as for canned meats, ham, and other salted meat products. The company's broad portfolio also features compounds such as ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, and L-lysine, among others. These diverse offerings are marketed under the proprietary brands Star Lake and Yue Bao.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1964 and headquartered in Zhaoqing, China, Star Lake Bioscience Co., Inc. specializes in the production and global distribution of pharmaceutical ingredients, as well as food and animal feed additives. Its extensive product catalog includes guanosine, which serves as a crucial intermediate for both food and pharmaceutical applications. The company also manufactures L-proline, a vital intermediate for synthesizing captopril and enalapril, and a raw material used in amino acid transfusions. Another key offering is Adefovir dipivoxil tablets, formulated to combat Hepatitis B by inhibiting HBV DNA polymerase activity and disrupting the virus's DNA. Additionally, L-threonine is provided for its application in animal feed premixes, particularly for pigs and poultry. Star Lake Bioscience further supplies disodium 5'-ribonucleotide, utilized in the treatment of chronic hepatitis, muscular atrophy, and certain eye conditions. Similarly, disodium 5-inosinate addresses issues like leukopenia, thrombocytopenia, and both acute and chronic hepatitis. Inosine is another significant product, prescribed for various ailments including chronic hepatitis, heart disease, low white blood cell or platelet counts, and central choroidoretinitis. Furthermore, disodium 5'-guanylate finds application in food preservation, such as for canned meats, ham, and other salted meat products. The company's broad portfolio also features compounds such as ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, and L-lysine, among others. These diverse offerings are marketed under the proprietary brands Star Lake and Yue Bao.
